Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,150,139
  • Shares Outstanding, K 96,813
  • Annual Sales, $ 59,610 K
  • Annual Income, $ -262,140 K
  • 60-Month Beta 1.14
  • Price/Sales 20.04
  • Price/Cash Flow N/A
  • Price/Book 13.30
Trade ARQT with:

Options Overview Details

View History
  • Implied Volatility 110.50% ( +11.95%)
  • Historical Volatility 102.06%
  • IV Percentile 52%
  • IV Rank 25.97%
  • IV High 339.03% on 10/19/23
  • IV Low 30.32% on 09/26/23
  • Put/Call Vol Ratio 3.07
  • Today's Volume 3,243
  • Volume Avg (30-Day) 3,052
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 48,278
  • Open Int (30-Day) 47,219

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.65
  • Number of Estimates 1
  • High Estimate -0.65
  • Low Estimate -0.65
  • Prior Year -1.31
  • Growth Rate Est. (year over year) +50.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.09 +12.21%
on 03/25/24
13.17 -22.55%
on 04/09/24
+0.09 (+0.89%)
since 03/12/24
3-Month
3.11 +227.96%
on 01/19/24
13.17 -22.55%
on 04/09/24
+6.56 (+180.22%)
since 01/12/24
52-Week
1.76 +479.55%
on 12/01/23
15.40 -33.77%
on 04/13/23
-3.06 (-23.08%)
since 04/12/23

Most Recent Stories

More News
S&P Futures Slip as Investors Cautiously Await U.S. Big Bank Earnings, U.S. Rates Stay in Focus

December S&P 500 futures (ESZ23) are trending down -0.24% this morning after three major U.S. benchmark indices closed lower on Thursday as hotter-than-expected U.S. inflation data bolstered bets on Federal...

ESZ23 : 4,694.27s (-0.58%)
DAL : 46.86 (-1.62%)
F : 12.61 (-3.30%)
BYND : 6.64 (-3.91%)
FAST : 70.45 (+0.82%)
JPM : 182.79 (-6.47%)
WFC : 56.47 (-0.39%)
C : 59.68 (-1.70%)
BLK : 763.40 (-2.87%)
PNC : 150.63 (-1.25%)
UNH : 439.20 (-0.57%)
DIM.FP : 250.600 (-1.80%)
Why Shares of Arcutis Biotherapeutics Fell This Week

The company released phase 3 trial results for an atopic dermatitis cream.

ARQT : 10.20 (-14.14%)
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
ARQT : 10.20 (-14.14%)
Why Shares of Arcutis Biotherapeutics Jumped This Week

The stock got a push when a British medical journal posted trials information on the company's lead product.

ARQT : 10.20 (-14.14%)
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

ARQT : 10.20 (-14.14%)
CDXC : 3.85 (-5.87%)
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis

/PRNewswire/ -- MyHealthTeam, creator of the largest and fastest-growing social networks for people living with chronic health conditions, today launched...

ARQT : 10.20 (-14.14%)
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

AVEO : 15.00 (unch)
ETON : 3.42 (-0.58%)
ARQT : 10.20 (-14.14%)
IMCR : 56.53 (-4.30%)
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

ARQT : 10.20 (-14.14%)
ANGN : 10.0000 (+2.04%)
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

/PRNewswire/ -- LifeArc today announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing...

ARQT : 10.20 (-14.14%)
NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING

/PRNewswire/ -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) today announced the launch of an educational campaign designed to raise awareness about the...

ARQT : 10.20 (-14.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 13.34
2nd Resistance Point 12.56
1st Resistance Point 11.38
Last Price 10.20
1st Support Level 9.42
2nd Support Level 8.64
3rd Support Level 7.46

See More

52-Week High 15.40
Last Price 10.20
Fibonacci 61.8% 10.19
Fibonacci 50% 8.58
Fibonacci 38.2% 6.97
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar